celcuity

EXPANDING TREATMENT OPTIONS

Unraveling Complex Cellular Activity to Develop Targeted Therapies

Corporate Presentation

August 2022

Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial condition, including but not limited to current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results and expected timing thereof, our plans to develop and commercialize gedatolisib, our first internally developed drug candidate, our plans to research, discover and develop additional product candidates, our planned wilkTORIA-1 Phase 3 clinical trial and the expected results of our upcoming VIKTORIA-1 Phase 3 clinical trial, including but not limited to our planned VIKTORIA-1 Phase 3 clinical trial and the expected results of our upcoming VIKTORIA-1 Phase 3 clinical trial, including but not limited to ur planned VIKTORIA-1 Phase 3 clinical trial and the expected results of our upcoming VIKTORIA-1 Phase 3 clinical trial, "intend," "plan," "would," "should," and "could," and similar expressions or words, identify forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Any forward-looking statements in this presentation are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this presentation, including, without limitation, risks relating to: (i) unforeseen delays in clinical trial enrollment or other activities that may affect the timing and success of our ongoing gedatolisib and CELsignia trials, (ii) the fact that preliminary data from a clinical study may not be predictive of the final results of such study or the results of other ongoing or future studies, (ii) unforeseen challenges in developing partnership opportuni

Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These known risks and uncertainties are described in our reports and filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

The information in this presentation does not provide full disclosure of all material facts relating to Celcuity, its securities or the proposed offering of its securities. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities.

Celcuity EXPANDING TREATMENT OPTIONS

Unraveling Complex Cellular Activity to Develop Potential First-in-Class Targeted Therapies





Gedatolisib is a Potential First-in-Class PI3K/mTOR Inhibitor

Granted Breakthrough Therapy Designation for 2L HR+ / HER2- advanced breast cancer indication

Highly Differentiated Mechanism	 First small molecule inhibitor of the PI3K/mTOR pathway administered intravenously Inhibits all isoforms of PI3K and mTOR at low or sub-nanomolar concentrations
Compelling Efficacy	 Compelling efficacy relative to 1st & 2nd line SOC with HR+/HER2- ABC with gedatolisib + ET + CDK4/6i Phase 1b trial (N=103) reported 62% ORR in evaluable patients across four expansion arms 31 months PFS in 1L arm and 12.9 months PFS in 2L arm with Phase 3 dosing schedule
Well-Tolerated	 Safety profile is well characterized - 492 patients treated with gedatolisib in eight clinical trials Only 4% treatment discontinuation with Phase 3 dosing - well-tolerated with manageable TEAE's Significantly lower Grade 3/4 hyperglycemia than approved oral PI3K-α inhibitor (7% vs. 37%)
Multiple Potential Indications	 Expect to initiate Phase 3 trial in mid-2022 for 2L+ patients with HR+ / HER2- advanced breast cancer Addresses 100K+ annual patient population globally Broad range of indications are possible given PI3K/mTOR's role in multiple tumor types
celcuity	

EXPANDING TREATMENT OPTIONS

PI3K/mTOR is One of Most Important and Complex Oncogenic Pathways

Key oncogenic driver and resistance mechanism for multiple oncogenic pathways

PI3K/mTOR regulates cell growth and metabolism

- Linked to multiple cell control decisions
- Can play a key role in driving cancer proliferation.
- Bypass resistance mechanism to CDK4/6, ER, AR, PARP inhibition



Tumor type	PIK3CA mutation	PTEN Loss or Mutated
ER+ BC ^{1,2}	~39% ¹	~46%
Endometrial ²	~37%	~82%
Cervix ²	~29%	~34%
HER2+ BC ^{1,2}	~25% ¹	~30%
Bladder ²	~22%	~35%
Colon ²	~17%	~51%
HNSCC ²	~14%	~36%
TNBC ^{1,2}	~13% ¹	~15%
Ovarian ²	~8%	~24%
Prostate ²	~6%	~66%



Difficult to Safely and Efficaciously Inhibit the PI3K/mTOR Pathway

Maximum efficacy requires inhibition of all Class 1 PI3K isoforms and mTORC1 and mTORC2

Multiple pathway components must be targeted

- Feedforward and feedback loops between PI3K isoforms and mTOR cross-activates uninhibited sub-units
- o Induces compensatory resistance that reduces efficacy

celcuity

Therapeutic window for oral PI3K or mTOR inhibitors is narrow

- Difficult to achieve optimal pathway inhibition without inducing undue toxicities in patients
- Orally administrated pan-PI3K or pan-PI3K/mTOR inhibitors induced unacceptable toxicity



Gedatolisib Has a Highly Differentiated Mechanism of Action

Only pan-PI3K/mTOR inhibitor known to be under active development

Gedatolisib differentially targets one of the most important and complex oncogenic pathways

- First pan-PI3K/mTOR inhibitor with low nanomolar potency that is well tolerated with manageable toxicities
- Pan-PI3K/mTOR inhibition limits cross-activation that can occur with PI3K isoform or mTOR specific drugs
- Enhances potential synergy with other pathway inhibitors

Gedatolisib vs. Approved Solid Tumor PI3Ki or mTORi IC₅₀ (nM)¹

Target	Gedatolisib ²	Alpelisib ³	Everolimus ⁴
ΡΙ 3Κ-α (ΜΤ)	0.6	~4.0	-
ΡΙ3Κ-α (WT)	0.4	4.6	-
ΡΙ3Κ-β	6.0	1,156	-
ΡΙ3Κ-γ	5.4	250	-
ΡΙ3Κ-δ	6.0	290	-
mTORC1	1.6	-	~2.0
mTORC2	1.6	-	-



(1) IC50 derived from cell-free biochemical dose response analysis; (2) Venkatesan 2010 for PI3K and mTORC1 IC50 values; (3) Fritsch 2014; (4) Schuler 1997; everolimus is an mTOR inhibitor that binds with high affinity to the FK506 binding protein-12 (FKBP-12), thereby forming a drug complex that inhibits the activation of mTOR

Gedatolisib PK Properties vs. Other Approved PI3K Inhibitors

Differentiated chemical structure results in favorable PK profile and lower toxicity

	Gedatolisib ¹	Alpelisib ²	Copanlisib ²	Duvelisib ²	Idelalisib ²
Target(s)	Pan-PI3K mTOR	ΡΙ3Κ-α	Pan-PI3K	ΡΙ3Κ-δ	ΡΙ3Κ-δ
Administration	IV	Oral	IV	Oral	Oral
Dosing (molar/month)	0.88	19.03	0.37	3.22	20.22
Volume of distribution (L)	30	114	871	29	23
AUC plasma (ug.h/mL)	47.1	33.2	1.6	7.9	10.6
Cmax (ug/mL)	8.6	2.5	0.5	1.5	1.9
Half-life (hours)	37	8-9	39	5	8
Hyperglycemia (G 3/4) ³	7%	37%	41%		
Treatment related SAE's ³	15%	35%	26%	65%	68%
Treatment related (TR) Discontinuations ³	4%	26%	16%	35%	17%

Gedatolisib vs. PI3K- α and pan-PI3K drugs

- o 80% lower rate of Grade 3/4 hyperglycemia
 - Due to gedatolisib's lower liver exposure
 - Alpelisib dosage 22x > geda (molar/month)
 - Copanlisib 50x > retention liver vs plasma
- $\,\circ\,$ 75%-85% lower rate of TR discontinuations
- $\,\circ\,$ 3.5x-20x higher C_{max}
- o 4x-30x more efficient distribution in plasma
- o 1.5x-30x higher AUC plasma

Gedatolisib vs. PI3K-δ drugs

- o 73%-97% lower dosage (molar/month)
- $\circ\,$ Minimal GI, liver, and infection-related AE's



Sources: 1) Shapiro 2015; B2151009 Arm D; internal Celcuity studies; 2) USPI; 3) No head-to-head trials have been conducted; data collected from different trials, in different patient populations and may not be comparable.



Gedatolisib for Advanced Breast Cancer (ABC)



Limited Benefit for 2nd Line HR+/HER2- ABC Patients Post-CDK4/6 Treatment

Finding more effective treatment for these patients is the biggest unmet need in breast cancer

2nd Line SOC HR+/HER2- Metastatic Breast Cancer (Post CDK4/6 inhibitor)

Treatment (Patient Group)	mPFS (months)	ORR ¹
Fulvestrant <i>(PIK3CA WT)</i>	1.9^{2,3}	6% ³
Everolimus (mTOR) + Exemestane ⁴ (PIK3CA WT)	Unknown	Unknown
Alpelisib (PI3K-α) + Fulvestrant ⁵ (PIK3CA MT)	5.6 - 7.3	17% - 24%

Treatment guidelines recommend use of sequential endocrine therapy before chemotherapy, in the absence of visceral crisis or until all endocrine therapy options have been exhausted.⁶



Abbreviations: ORR = objective response rate; PFS = progression free survival; WT = wild type; MT = mutant; NR = not reported Sources: (1) ORR is for patients with measurable disease; (2) Bardia 2021, EMERALD trial; (3) Lindeman 2021, VERONICA trial; (4) No prospective clinical trials have been conducted for this regimen in this patient population; (5) Rugo 2021, BYLieve trial; (6) B Moy 2021, JO Brett 2021; GJ Lindeman 2021.

Clinical Development Plan

Phase 3 study for patients with HR+/HER2-ABC who progressed on CDK4/6 therapy

- Expect to initiate a pivotal Phase 3 clinical trial for gedatolisib with palbociclib + fulvestrant in mid-2022
- All-comer design (PIK3CA+/-) that will incorporate separate primary endpoints for mutated and nonmutated PIK3CA patients
- FDA granted Breakthrough Therapy Designation for this indication in July 2022.

Significant potential indications based on POC and nonclinical study data

- Treating hormonally driven cancers has strong biological rationale
 - Prostate cancer
 - Nonclinical and clinical studies demonstrate linkage between androgen and PI3K/mTOR pathways
 - Recurrent endometrial cancer
 - Ovarian cancer
 - Favorable data from POC study
 - ORR = 80%

Review of Preliminary Phase 1b Data



PI3K/mTOR, ER, and CDK4/6 are Interdependent Signaling Pathways

PI3K/mTOR is a key resistance mechanism to estrogen and CDK4/6 therapies

Treatment Strategy

- Simultaneously blocking interdependent ER, PI3K, mTOR & CDK signaling pathways in ER+ breast cancer addresses ER and CDKi resistance mechanisms
- Inhibiting all PI3K isoforms and mTORC1/2 prevents resistance mechanisms that occur when only PI3K-α or mTOR are inhibited
- Leads to improved response rates and duration of response



B2151009: Phase 1b Study (138 patients)

Dose escalation and safety/efficacy expansion (early signals of clinical activity)



63% ORR and 12.9 months PFS in Arm D with Phase 3 Dosing Schedule

ORR and PFS was superior to SOC in each arm for their respective lines of therapy

B2151009 Efficacy Summary (N=103)				
Patients	1L: CDKi-Naïve	2L+: CDKi-naïve	2L/3L: CDKi-pretreated	2L/3L: CDKi-pretreated
Arm	A	B	C	D
	(N=31)	(N=13)	(N=32)	(N=27)
Study Treatment	G+ P + L	G + P + F	G + P + F	G + P + F
	(weekly)	(weekly)	(weekly)	(3 week on/1 week off)
ORR ¹	85%	77%²	32%^{2,3}	63%^{2,3}
(95% CI)	(66%-96%)	(46%-95%)	(16%-52%)	(42%-81%)
DCR ⁴	96%	100%	79%	96%
(95% CI)	(81%-~100%)	(75%-100%)	(59%-92%)	(81%-~100%)
Median PFS (mos)	31.1	11.9	5.1	12.9
(95% CI)	(16.9, NR)	(3.7, NR)	(3.4, 7.5)	(7.4, 16.7)

Abbreviations: G = gedatolisib; P = palbociclib; L = letrozole; F = fulvestrant; CBR = clinical benefit rate; NR = not reached

(1) ORR represents PR, except in Arm A, which had 1 CR. Responses by Physician Assessment per RECIST 1.1; (2) Includes 2 unconfirmed PR; (3) ORR was superior in Arm D relative to Arm C in patients regardless of the number of prior therapies for ABC. In Arm C and Arm D, ORR for patients receiving 1 prior line of therapy was 33% and 56% respectively and for \geq 2 prior lines of therapy it was 32% and 78%; (4) DCR is clinical benefit rate. Source: Layman 2021 SABCS. Data presented for gedatolisib is from a preliminary data analysis as of a cutoff date of May 10, 2021, representing a database snapshot, and may change based on ongoing routine data monitoring



Gedatolisib + Palbociclib + Letrozole in 1st Line HR+/HER2- ABC (N=31)¹

Data compares favorably to published data for SOC palbociclib + letrozole therapy from PALOMA-2²



Celcuity EXPANDING TREATMENT OPTIONS

(1) Layman 2021 SABCS; Arm A data from B2151009 study. (2) Finn 2016 NEJM. Note: (1) ORR reported is for patients with measurable disease. (2) No head-to-head trials have been conducted; data collected from different trials, in different patient populations and may not be comparable. (3) Data presented is from a preliminary data analysis as of a cutoff date of May 10, 2021, representing a database snapshot, and may change based on ongoing routine data monitoring

Gedatolisib + Palbociclib + Fulvestrant in 2nd/3rd Line HR+/HER2- ABC Patients

Data from Phase 1b study with Phase 3 regimen (Arm D) compares favorably to published data with current SOC (N=27)





Source: Layman 2021 SABCS. Arm D data from B2151009 study. Data presented is from a preliminary data analysis as of a cutoff date of May 10, 2021, representing a database snapshot, and may change based on ongoing routine data monitoring.

Adding Gedatolisib to Palbociclib + ET Resulted in Higher ORR (1.5-2.5x)

Arm D vs. PALOMA-3 ORR and PFS results are particularly significant since PALOMA-3 patients were CDKi-naïve

Patients	1L CDKi-naïve		1L+ CDKi-naïve	2L/3L Prior CDKi
Study	PALOMA-2 ¹	Arm A ²	PALOMA-3 ³	Arm D ²
Evaluable Patients	N=338	N=27	N=267	N=27
Study Treatment	Palbociclib + Letrozole	Gedatolisib + Palbociclib + Letrozole	Palbociclib + Fulvestrant	Gedatolisib + Palbociclib + Fulvestrant
ORR (evaluable patients) (95% CI)	55% (50%-61%)	85% (66%-96%)	25% (20%-30%)	63% ⁵ (42%-81%)
Median PFS (months) (95% CI)	24.8 (22.1, NR)	31.1 (16.9, NR)	9.5 (9.2, 11.0)	12.9 (7.4, 16.7)

- Arm A ORR 1.55 times higher than PALOMA-2 (85% vs. 55%)
- Arm D ORR 2.52 times higher than PALOMA-3 (63% vs. 25%)



Source: (1) Finn 2016 NEJM. (2) Layman 2021 SABCS; (3) Turner 2015 NEJM Note: No head-to-head trials have been conducted; data collected from different trials, in different patient populations and may not be comparable. Abbreviations: ET = endocrine therapy

Gedatolisib Combo vs. SOC Benchmarks for 2L HER+ / HER2- ABC Post-CDKi

Gedatolisib Combo Offers Potential for Superior Efficacy Compared to SOC Options

2 nd Line ER+/HER2- MBC (post-CDKi)		
Drug Regimen	ug Regimen Efficacy	
Gedatolisib + Palbociclib + Fulvestrant ¹	PFS 12.9 months	
(PIK3CA WT <u>and</u> MT patients)	ORR 63%	
Alpelisib + fulvestrant ²	PFS 5.6-7.3 months	
(PIK3CA MT patients only)	ORR 21%	
Fulvestrant ³	PFS 1.9	
(PIK3CA WT patients only)	ORR 6%	
Everolimus + Exemestane ⁴ (PIK3CA WT patients only)	Unknown	



Sources: (1) Layman 2021 SABCS. (2) Rugo 2020 SABCS – BYLlieve trial; Rugo 2021 SABCS – BYLieve trial (3) Bardia 2021, EMERALD trial mPFS only; Lindeman 2021, VERONICA trial mPFS and ORR; (4) No prospective clinical trials have been conducted for this regimen in this patient population; Abbreviations: WT = wild type; MT = mutation Note: No head-to-head trials have been conducted; data collected from different trials, in different patient populations and may not be comparable.

Arm D: Duration of Treatment in Patients' Refractory to Prior Therapy

Gedatolisib treatment duration significantly greater than patient's prior line of therapy

Duration of Immediate Prior Treatment (DIPT)					
DIPT <180 Days DIPT <365 Days					
Arm	D	D			
# Evaluable patients with DIPT <185 or 365 days (% of evaluable)	7 (27%)	11 (42%)			
Median DIPT (days)	106	155			
Median Duration of Study Treatment (DST, days)	270	276			
Ratio of median DST vs. DIPT	2.6	1.8			
Objective Response Rate to Study Treatment (95% CI)	71% (29%-96%)	73% (39%-94%)			

Source: Layman 2021 SABCS

Data presented for gedatolisib is from a preliminary data analysis as of a cutoff date of May 10, 2021, representing a database snapshot, and may change based on ongoing routine data monitoring



Arm D: High ORR Irrespective of Number of Prior Lines of Therapy

Number of Prior Lines of Therapy for Advanced Disease			
	≥ 2 Prior Lines	1 Prior Line	
# of Evaluable Patients	9	18	
# of Partial Responses	7	10	
Objective Response Rate	78%	56%	

Source: Layman 2021 SABCS

Data presented for gedatolisib is from a preliminary data analysis as of a cutoff date of May 10, 2021, representing a database snapshot, and may change based on ongoing routine data monitoring



Safety Summary: Treatment-Emergent Adverse Events

G + P + ET was well tolerated overall; < 4% discontinuation rate with Phase 3 dosing (Arm D)

Phase 1 Trial: Gedatolisib alone¹ (154 mg weekly IV)

	All Arms (n=42)			
	TEAE's > 20%			
	All Grades	Grade 3	Grade 4	
Adverse Event	%	%	%	
Stomatitis	55	7	-	
Nausea	41	2	-	
Hyperglycemia	26	2	-	
Vomiting	24	2	-	
Asthenia	21	2	-	
Appetite decrease	21	-	-	
Fatigue	21	-	-	

Phase 1b Trial – Arm D: G + P + F²

- Only <4% discontinued drug due to AE
 - Alpelisib 26% discontinued³
- 33% on treatment for >15 mos
- Few hyperglycemia-related adverse events (22% all Grades, 7% Grade 3/4)
 Alpelisib (79% all, 39% Grade 3/4)³
- $_{\odot}~$ Most TEAE's were Grade 1 or 2
- Stomatitis was treated at manifestation, not prophylactically
 - Prophylactic treatment reduces G2 incidence by 90%; G3 by 100%⁴
 - Phase 3 study will include prophylaxis
- Neutropenia, leukopenia, and anemia AEs related to palbociclib

Phase 1b Trial – Arm D: $G + P + F^2$

(180 mg IV, 3 weeks, one week off)

	Arm D (n=27)			
	TEAE's > 30%			
	All Grades	Grade 3	Grade 4	
Adverse Event	%	%	%	
Neutropenia	85	59	11	
Stomatitis	85	22	-	
Nausea	74	-	-	
Fatigue	67	7	-	
Dysgeusia	52	-	-	
Leukopenia	41	19	4	
Diarrhea	41	4	-	
Vomiting	37	4	-	
Constipation	37	4	-	
Hyperglycemia	22	7	-	



Source: (1) Shapiro 2015; (2) Layman 2021 SABCS; (3) USPI Alpelisib; (4) Rugo 2017. Abbreviations: ET = endocrine therapy; G = gedatolisib; P = palbociclib; F = fulvestrant; TEAE = treatment emergent adverse events; AE = adverse event Note: Data presented for the B2151009 trial is from a preliminary data analysis as of a cutoff date of May 10, 2021

Gedatolisib + Paclitaxel + Carboplatin in Patients with Solid Tumors (N=17)¹

65% ORR in all patients, 82% ORR in patients with ovarian cancer



- Ovarian Cancer (N=11)
 - ORR: 82%
 - Clear cell ovarian cancer (CCOC) (N = 10)
 - ORR: 80% 5/10 PR, 3/10 CR
 - Low grade serous ovarian (N=1)
 - 1/1 PR
- Other solid tumors (N= 6)
 - ORR = 33%
- Median PFS = 6.35 months (95% CI 4.6-11.11)
- Median duration of response = 7.6 months (95% Cl 1.9-13.4)
- The CCOC data compares very favorably to ORR for platinum therapy reported in platinum-naïve CCOC patients 25%-50%
- CCCO accounts for ~15% ovarian cancers in Asia
- Will assess likelihood other ovarian sub-types may benefit from gedatolisib + platinum therapy



Source: (1) Columbo 2021 CCR

65% ORR for Patients Receiving Gedatolisib + Trastuzumab Biosimilar¹



* Target lesion decreased by 63% but a new leptomeningeal seeding occurred.
** Unconfirmed response

- 11 of 17 (%) showed partial response (PR), including 1 unconfirmed
- \circ 4 of 17 (24%) had stable disease (SD)

Duration of Response



* Unconfirmed response

o Median duration of response 7.1 months



Source: (1) Kim 2021 SABCS. Includes 1 unconfirmed response. Note: Data presented is from an interim analysis of data as of a cutoff date of October 30, 2021, representing a database snapshot, and may change based on ongoing routine data monitoring and enrollment.

Phase 3 Study Design VIKTORIA-1



Pivotal Trial Design Considerations for 2nd Line HR+/HER2- ABC

- Standard-of-care 2nd line treatment differs based on *PIK3CA* status
 - PIK3CA wildtype (WT): Fulvestrant or everolimus + exemestane
 - PIK3CA mutated (MT): Alpelisib + fulvestrant
- 35% of patients have *PIK3CA* mutations in HR+/HER2- breast cancer
- Must formally test efficacy for each *PIK3CA* sub-group (WT and MT)
- PFS is the standard primary end point for randomized studies in 1st/ 2nd line HR+/HER2- ABC
 - Pivotal studies for all current FDA approved therapies used PFS

Supports design with multiple primary endpoints in different sub-groups



VIKTORIA-1 Pivotal Phase 3 Trial Design Overview





1) Optional Cross-over to Arm A or Arm B upon progressive disease; WT = wild type; MT = mutant; PFS = progression free survival

Relevant Clinical Trial Results for VIKTORIA-1 Study Arms

Each trial evaluated patients who received prior treatment with a CDK4/6 therapy

	Gedatolisib + + Fulves N=27	Palbociclib strant 7 ¹	Fulvestrant N=165⁴	Fulvestrant N=52 ⁶	Alpelisib + Fulvestrant N=126 ⁷	Alpelisib + Fulvestrant N=121 ⁸
PIK3CA Status	/ WT (67% / 3	M 33%)	WT	WT / MT (70% / 30%)	Μ	М
Line of Therapy (% by line)	2L / 3 (67% / 3	BL+ 33%)	2L / 3L+ (NR) ⁵	2L / 3L+ (83% / 17%)	2L/ 3L+ (37%/ 63%)	1L / 2L/ 3L+ (12% / 70% / 19%)
mPFS (months)	12.9		1.9	1.9	5.6	7.3
ORR	63% (ove <u>WT</u> 59%	erall) ^{2,3} <u>M</u> 78%	NR	6%	22%	17%
PFS % at 12 months	53.2% (ov <u>WT</u> 48.5%	verall) ³ <u>M</u> 60.0%	10%	12%	22%	27%



Sources: (1) Layman 2021 SABCS – B2151009 Trial, Arm D; (2) Includes 2 unconfirmed PR. (3) WT and MT sub-group data is from internal Celcuity analysis. (4) Bardia 2021 SABCS – EMERALD trial; (5) Prior lines of therapy was only reported for the control population as a whole, of which 59% had only one prior line of endocrine therapy. The 165 patients treated with fulvestrant represented 69% of the total control population. (6) Lindeman 2021, VERONICA trial; (7) Rugo 2021 – SABCS (8) Rugo 2021 – Lancet. Note: No head-to-head trials have been conducted; data collected from different trials, in different patient populations and may not be comparable. Data presented for gedatolisib is from a preliminary data analysis as of a cutoff date of May 10, 2021 and may change based on ongoing routine data monitoring.

VIKTORIA-1 Pivotal Study Features

- Global open-label randomized study
- Key eligibility criteria:
 - Any PIK3CA status
 - Progressed on prior CDK4/6 treatment
 - Any menopausal status
 - < 2 prior endocrine therapy
- Three primary endpoints could support three separate indications
 - Two co-primary endpoints (PFS) in PIK3CA WT patients
 - One primary endpoint (PFS) in *PIK3CA* MT patients
- Three-arm design for *PIK3CA* WT and MT patients enables evaluation of two different regimens and shows contribution of gedatolisib
- Stratification by geography, prior treatment response (≤ or > 6 months), presence of liver or lung metastasis (yes/no)

Designed to support indications for gedatolisib and fulvestrant with or without palbociclib as second or third treatment for patients with HR+/HER2- advanced or metastatic breast cancer who have progressed on prior treatment with a CDK4/6 therapy in combination with Al





Experienced drug development team



Celcuity EXPANDING TREATMENT OPTIONS

Leading cancer KOLs are participating in our research

Clinical Advisory Board



Mark Pegram M.D. Ph.D.

Stanford University



Hung Khong M.D.



Sara Hurvitz M.D.

Ucla



Bora Lim M.D.

Baylor College of Medicine



Ben Ho Park M.D., Ph.D.

VANDERBILT UNIVERSITY



Mothaffar Rimawi M.D.

Baylor College of Medicine



Adam Brufsky M.D., Ph.D.

UPPMC LIFE CHANGING MEDICINE



Alberto Montero M.D.

University Hospitals The Science of Health. The Art of Compassion



Lee Schwartzberg M.D.







Carol Lange Ph.D. 丞 UNIVERSITY OF MINNESOTA



Manfred Auer Ph.D. THE UNIVERSITY of EDINBURGH

John Katzenellenbogen Ph.D.





Ron McGlennen M.D.

access genetics 🗲



Benita Katzenellenbogen Ph.D.



celcuity EXPANDING TREATMENT OPTIONS

32

Celcuity Leadership Team

Co-Founder and CEO



Brian Sullivan

CEO, Founder - PUR Water Filters

- Sold to Proctor & Gamble in 1999 for \$265 million
- CEO SterilMed, med devices • Sold to Johnson & Johnson
 - in 2011 for \$330M

A.B. Harvard University, magna cum laude with distinction

7 U.S. patents received 4 U.S. patents pending

Co-Founder and CSO



Lance Laing, PhD Scientist at Scriptgen/Anadys (purchased by Novartis)

Director of Chemistry and Product Development for two instrument companies

PhD in biophysics and biochemistry - The Johns Hopkins University

Post-doc: Washington Univ. as NIH fellow

19 U.S. patents received 25 U.S. patents pending

CFO



Vicky Hahne

CFO – SimonDelivers (on-line grocery)

Controller – Respirtech (medical devices)

Controller – SterilMed (medical devices)

15 years as controller and CFO at high-growth VC and PE backed companies

CBO



Eric Lindquist

Global VP of BD at Natera (Signatera)

Global VP of CDx at Asuragen CBO Cynvenio (CTC HER2, EGFR test)

Director of CDx at Ventana / Roche

Celcuity EXPANDING TREATMENT OPTIONS

Gedatolisib – A Phase 3 Ready Asset with Multiple Potential Indications

Phase 1b data in HR+/HER2- MBC reported better ORR and PFS than SOC in 1st and 2nd lines

Compelling Efficacy in Advanced Breast Cancer	Multiple Potential Indications	Key Milestones	Financial Resources
	\bigcirc	222 222	
 Very promising results from Arm D of Phase 1b (basis for Phase 3) 63% ORR, 12.9 months mPFS High ORR and PFS rate at 12 mo for both – PIK3CA MT and PIK3CA WT <4% discontinuation rate 	 Numerous other tumor (ypes involve PI3K/mTOR signaling) Compelling POC clinical data with PI3K therapies that have inferior MOA, higher toxicity Prostate, endometrial, cervical, and head & neck cancers involve PI3K/mTOR pathway 	 Laying groundwork for cobust development plan Enrollment for VIKTORIA-1 Phase 3 study to begin in 2H '22 Lifecycle development update in 2H '22 	 Strong balance sheet \$66.9 million cash on hand at end of Q2 2022 Entered into \$100 million private placement agreement in Q2 2022 expected to close in 2H '22 Entered into \$75 million debt agreement in Q3 2022

EXPANDING TREATMENT OPTIONS

34



Live tumor cells contain infinitely more data than the fragmented cells current cancer diagnostics use

CELsignia

The CELsignia platform captures this data

Researchers recognize need for alternatives to genomic analysis

Complexity of signaling pathway networks requires much greater data to characterize than genomics can provide



Network:

events

CELsignia – the first 3rd generation diagnostic

Measures dynamic cell signaling activity to identify cancer drivers genomic tests cannot detect

Cell Signaling

Quantified





>100,000 patient tumor cells are isolated in a proprietary cell microenvironment

Cell pathways are activated to generate data from >10²⁰ cellular events at 240 time points to create a

"movie" of the signaling activity¹

0100

Algorithmic Analysis



A proprietary algorithm analyzes this "big data" set to identify signaling activity 5 standard deviations from normal



Current Molecular Diagnostics vs. CELsignia – HER2 Example

CELsignia identifies new sub-group of patients with HER2 driven cancer

FISH HER2 Dx (1 pathway gene)





CELsignia HER2 Activity (4 hours of pathway signaling events)



\$9 billion anti-HER2 drug annual revenue¹ CELsignia identifies new patients for anti-HER2 drugs

\$Billions additional anti-HER2 drug revenue potential



Key research discoveries drive test development

CELsignia platform provides powerful tool to discover new cancer sub-types and mechanisms

Specific target mutations (e.g. HER2+) not required for oncogenic signaling

- Discovered 16 cancer sub-types that genomic tests cannot detect
- Confirms mutational status is not sufficiently specific

Implications

celcuity

 May miss 50% of HER2, EGFR, PI3K, c-Met driven cancers Mutations often don't lead to oncogenic signaling

- Demonstrated that target specific mutations often do not drive aberrant signaling
- Further confirms mutational status is not sufficiently specific

Implications

 Explains low response rates of many targeted therapies Drug resistance mechanisms characterized

• Linkages identified between:

- c-Met, HER3, HER2, & EGFR
- LPA, S1PA, PI3K, MEK
- Untreated cooperative pathways drives drug resistance

Implications

May miss 50% of HER2, EGFR,
 PI3K, c-Met driven cancers

CELsignia CDx identifies new patients for targeted therapies



celcuity s

Celcuity is a clinical stage biotechnology company that discovers previously undetectable cancer drivers and develops drugs to treat them.



Our third-generation cellular analysis platform unravels complex oncogenic activity molecular tests can't detect.



We harvest these insights to develop new targeted therapies for cancer patients

